2018
Treatment of infrapopliteal post-PTA dissection with tack implants: 12-month results from the TOBA-BTK study
BRODMANN, Marianne, Christian WISSGOTT, Andrew HOLDEN, Robert STAFFA, Thomas ZELLER et. al.Základní údaje
Originální název
Treatment of infrapopliteal post-PTA dissection with tack implants: 12-month results from the TOBA-BTK study
Autoři
BRODMANN, Marianne (40 Rakousko, garant), Christian WISSGOTT (276 Německo), Andrew HOLDEN (554 Nový Zéland), Robert STAFFA (203 Česká republika, domácí), Thomas ZELLER (276 Německo), Thodur VASUDEVAN (554 Nový Zéland) a Peter SCHNEIDER (840 Spojené státy)
Vydání
Catheterization and Cardiovascular Interventions, Hoboken, Wiley-Blackwell, 2018, 1522-1946
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 2.551
Kód RIV
RIV/00216224:14110/18:00104168
Organizační jednotka
Lékařská fakulta
UT WoS
000440646400023
Klíčová slova anglicky
balloon angioplasty; critical limb ischemia; dissection; infrapopliteal arteries; peripheral artery disease; tibial artery
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 11. 2. 2019 15:42, Soňa Böhmová
Anotace
V originále
Objectives: The Tack implant is designed for focal, minimal metal management of dissections. This study evaluated Tacks for treating postpercutaneous transluminal angioplasty (PTA) dissection in patients with below-the-knee (BTK) arterial occlusive disease. Background: PTA is the most commonly used endovascular treatment for patients with occlusive disease of the BTK vessels. Post-PTA dissection is a significant clinical problem that results in poor outcomes, but currently there are limited treatment options for managing dissections. Methods: This prospective, single-arm study evaluated patients with CLI and BTK lesions; 11.4% were Rutherford category (RC) 4 and 88.6% were RC 5. BTK occlusive disease was treated with standard PTA and post-PTA dissections were treated with Tack placement. The primary safety endpoint was a composite of major adverse limb events (MALE) and perioperative death (POD) at 30 days. Other endpoints included: device success; procedure success (vessel patency in the absence of MALE); freedom from clinically driven target lesion revascularization (CD-TLR); primary patency; and changes in RC. Data through 12 months are presented. Results: Thirty-two of 35 (91.4%) patients had post-PTA dissection and successful deployment of Tacks. Procedural success was achieved in 34/35 (97.1%) patients with no MALEs at 30 days. The 12-month patency rate was 78.4% by vessel, 77.4% by patient, and freedom from CD-TLR was 93.5%. Significant (P < .0001) improvement from baseline was observed in RC (75% of patients improved 4 or 5 steps). Conclusion: Tack implant treatment of post-PTA dissection was safe and effective for treatment of BTK dissections and resulted in reasonable 12-month patency and low rates of CD-TLR.